Sangamo Therapeutics, Inc.
NASDAQ:SGMOBiotechnology
+$0.00 today
- Market cap
- $70.43M
- Beta
- 1.29
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$0.32
Volume 0.61M
Average 9.53M
SGMO Net Income
Bottom-line profit after all expenses, interest, and taxes.
Sangamo Therapeutics, Inc.NASDAQ: SGMO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$31M, compared with -$30.6M a year earlier. Trailing-twelve-month net income was -$123.33M.
Context
- Net income amounted to 310.8% of revenue in FY2025, up 141.4 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$94.1M (+23.5%) for the fiscal year ending Dec 2026, a step up from the -25.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$31M+17.2% QoQ
- Last fiscal yearDec 2025
- -$122.93M-25.5% YoY
- LTMMar 2026
- -$123.33M-55.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -1.3% | -31.6% | -30.3 pp |
| 1 year | -25.5% | +23.5% | +49.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (122.93M) USD
- Year-over-year change
- -25.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (122.93M) | -25.5% |
| FY2024 | 2024-12-31 | (97.94M) | +62.0% |
| FY2023 | 2023-12-31 | (257.83M) | -34.1% |
| FY2022 | 2022-12-31 | (192.28M) | -7.8% |
| FY2021 | 2021-12-31 | (178.29M) | — |
Net Income vs competitors
How SGMO compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -55.2% is the 10th highest of 11, against a peer median of +0.9%.
- Net income amounts to 356.9% of revenue for SGMO, versus a peer median of 929.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$29.44M USD | +1.2% | — | 929.1% | |
| LTM Mar 2026 | -$31.99M USD | +57.0% | — | 41.0% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -$47.84M USD | +17.8% | — | 2454.6% |
| FY2025 | -€49.18M EUR | +0.6% | — | 1764.5% | |
| LTM Mar 2026 | -$54.28M USD | +11.4% | — | 187.7% | |
| LTM Mar 2026 | -$68.36M USD | -31.7% | — | 3832.0% | |
| LTM Mar 2026 | -CHF 72.06M CHF | -17.4% | — | — | |
| LTM Mar 2026 | -$77.6M USD | +45.6% | — | 138.9% | |
| LTM Mar 2026 | -$103.8M USD | -0.5% | — | 297.8% | |
| LTM Mar 2026 | -$123.33M USD | -55.2% | — | 356.9% | |
| LTM Mar 2026 | -$282.61M USD | -66241.3% | — | 9554.2% | |
| Peer median (excluding SGMO) | — | +0.9% | — | 929.1% | |
Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 110.7M | 111.3M | 176.23M | 57.8M | 39.55M |
| Cost of Revenue | 0 | 12.11M | 0 | 0 | 7.6M |
| Gross Profit | 110.7M | 99.19M | 176.23M | 57.8M | 31.95M |
| Gross Margin | 100.0% | 89.1% | 100.0% | 100.0% | 80.8% |
| Research & Development | 230.82M | 249.9M | 234.06M | 111.52M | 112.67M |
| Selling, General & Admin | 63.22M | 62.68M | 61.17M | 44.73M | 34.89M |
| Operating Expenses | 294.04M | 300.47M | 450.24M | 161.77M | 139.95M |
| Depreciation & Amortization | 17.64M | 12.11M | 22.19M | 9.36M | 7.6M |
| EBITDA | (160.35M) | (179.74M) | (96.8M) | (89.09M) | (115.9M) |
| EBITDA Margin | -144.9% | -161.5% | -54.9% | -154.1% | -293.0% |
| Operating Income | (183.34M) | (201.28M) | (274.01M) | (103.97M) | (108M) |
| Operating Margin | -165.6% | -180.8% | -155.5% | -179.9% | -273.1% |
| Interest Income | 5.35M | 9.43M | 11.1M | 5.86M | 1.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 5.35M | 9.43M | 11.1M | 5.86M | (15.5M) |
| Income Before Tax | (177.99M) | (191.85M) | (262.9M) | (98.11M) | (123.5M) |
| Pre-Tax Margin | -160.8% | -172.4% | -149.2% | -169.7% | -312.2% |
| Income Tax Expense | 306K | 429K | (5.07M) | (167K) | (568K) |
| Net Income | (178.29M) | (192.28M) | (257.83M) | (97.94M) | (122.93M) |
| Net Margin | -161.1% | -172.8% | -146.3% | -169.4% | -310.8% |
| EPS (Basic) | (1.23) | (1.25) | (1.48) | (0.49) | (0.44) |
| EPS (Diluted) | (1.23) | (1.25) | (1.48) | (0.49) | (0.44) |
| Weighted Avg Shares | 144.57M | 154.35M | 174.44M | 201.7M | 280.19M |
| Weighted Avg Shares (Diluted) | 144.57M | 154.35M | 174.44M | 201.7M | 280.19M |
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
Intrinsic Alpha fair value
Locked
Current Price
$0.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.